Eller D A, Austin P F, Tanguay S, Homsy Y L
Division of Pediatric Urology, Tampa General Hospital Children's Medical Center, University of South Florida, USA.
Eur Urol. 1998;33 Suppl 3:25-9. doi: 10.1159/000052238.
The objective of this study was to identify a cost-effective method of predicting a therapeutic response to desmopressin (DDAVP) by correlating daytime functional bladder capacity, age and urine osmolalities in patients with monosymptomatic nocturnal enuresis.
Thirty-five children out of 51 who initially presented to our institutions were included in the study. The remainder was excluded for lack of complete data. Constipation was actively addressed and was managed by administration of evening enemas for 3 consecutive days and dietary adjustment prior to initiating the study. Each micturition as measured throughout the day and the maximal daytime functional bladder capacity was determined as the largest void over a 2-day period. Urine samples were collected at home at 08:00, 16:00 and 22:00 (times that would best reflect the fluctuations in plasma vasopressin levels). Intranasal DDAVP was then administered, titrating the dose over a 2-week period. The initial dose was 10 micrograms and the dose was increased 10 micrograms every 3 days.
The response to DDAVP was then evaluated and of the 35 children, 27 demonstrated a complete response to DDAVP (all at doses between 10 and 30 micrograms). These were then related to the possible predictive factors. There was a significant correlation between a high maximum daytime functional bladder capacity and response to DDAVP (p = 0.006). Similarly, age was also predictive of a good response to DDAVP treatment (p = 0.008). However, spot urine osmolalities were not predictive of a response to DDAVP (p > 0.1).
Functional bladder capacity is a reliable predictor of response to desmopressin; children with larger capacities are more likely to exhibit a successful response. Older children have a better response rate than younger ones. Spot urine osmolality measured on specimens collected in the home setting is not predictive of response to desmopressin.
本研究的目的是通过关联单症状性夜间遗尿症患者的日间功能性膀胱容量、年龄和尿渗透压,确定一种预测去氨加压素(DDAVP)治疗反应的经济有效方法。
最初到我们机构就诊的51名儿童中有35名被纳入研究。其余因缺乏完整数据而被排除。在研究开始前,积极处理便秘问题,通过连续3天给予夜间灌肠和饮食调整来进行管理。测量全天的每次排尿量,并将最大日间功能性膀胱容量确定为2天内最大的排尿量。在家中于08:00、16:00和22:00(最能反映血浆血管加压素水平波动的时间)采集尿液样本。然后给予鼻内DDAVP,在2周内滴定剂量。初始剂量为10微克,每3天剂量增加10微克。
然后评估对DDAVP的反应,在35名儿童中,27名对DDAVP表现出完全反应(所有剂量在10至30微克之间)。然后将这些与可能的预测因素相关联。最大日间功能性膀胱容量高与对DDAVP的反应之间存在显著相关性(p = 0.006)。同样,年龄也是DDAVP治疗良好反应的预测指标(p = 0.008)。然而,即时尿渗透压不是DDAVP反应的预测指标(p > 0.1)。
功能性膀胱容量是对去氨加压素反应的可靠预测指标;容量较大的儿童更有可能表现出成功的反应。年龄较大的儿童比年龄较小的儿童反应率更高。在家中采集的样本上测量的即时尿渗透压不能预测对去氨加压素的反应。